This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
The Big Market Report Take
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- SNDL Remains 'Hold' Amid Sector UncertaintySeeking Alpha19m ago
- Hawkish RBA Provides Support For AUD/USD; Bulls Need To Break Back Above 0.7140Seeking Alpha19m ago
- Can Central Bankers Unpoke the Iran Bear?Bloomberg Markets32m ago
- AWP Vs. RQI: The Global Underdog Is A Better Buy In 2026Seeking Alpha34m ago
- Politics And The Markets 03/17/26Seeking Alpha44m ago